ANN ARBOR, Mich., April 14, 2011 /PRNewswire/ — Adeona
Pharmaceuticals, Inc. (AMEX:
AEN), a developer of innovative medicines for serious central
nervous system diseases, announced today that it will hold a
conference call/audio webcast to discuss the results from the
clinical study evaluating reaZin for the dietary management
of Alzheimer’s disease and mild cognitive impairment on Friday,
April 15, 2011, at 8:00 a.m. (HAST)/2:00 p.m. (EDT). James S. Kuo,
M.D., M.B.A., Adeona’s Chief Executive Officer and Diana Pollock,
M.D., Lead Principal Investigator of the study at Morton Plant
Neuroscience Institute on the campus of Morton Plant Hospital, will
host the call.
Interested parties should call toll free 1-800-860-2442
(U.S.) or 1-866-605-3852 (Canada), or from outside North America +1
412-858-4600, fifteen minutes before the start of the call to
register and identify themselves as registrants of the ‘Adeona’
Conference Call. Any registered caller on the toll free line may
ask to be placed in the queue for the Question & Answer
session. The call will be simulcast on the web at http://www.videonewswire.com/event.asp?id=78671.
If you are unable to participate during the live call, the webcast
will be available for replay at www.adeonapharma.com for 30
days after the call.
As a reminder, Dr. Pollock will present the poster titled
“Clinical Trial Results of the First Controlled Clinical Trial of
Zinc-Based Therapy for Alzheimer’s Disease and Mild Cognitive
Impairment” at the 63rd Annual Meeting of the American Academy of
Neurology. The poster presentation will be held today, April 14,
2011, from 2:00 to 6:30 p.m. (HAST)/8:00 p.m. to 12:30 a.m. (EDT)
at the Hawaii Convention Center in Honolulu, Hawaii. Adeona plans
to distribute a concurrent press relea
‘/>”/>
